Coronary Arteriosclerosis, Coronary Artery Disease, Hydroxymethylglutaryl-CoA Reductase Inhibitors
Conditions
Keywords
coronary artery disease, coronary computed tomography angiography, statins, coronary atherosclerosis
Brief summary
Assessment of Change in AtheROSclerotic Plaque by Serial CCTA (ACROSS) is designed as a prospective observational study which aim is to demonstrate the effect of statins on coronary atherosclerosis, assessed by quantitative analysis of CCTA.
Interventions
DRUGAtorvastatin
Patients diagnosed with coronary artery disease by CCTA be enrolled. Among enrolled patients, patients who is indicated to statin treatment according to the current ACC/AHA guideline will be treated with atorvastatin.
Sponsors
Chong Kun Dang Pharmaceutical Corp.
Yonsei University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients who underwent clinically indicated CCTA (index CCTA) * Mild to moderate stenosis (25-69%) on CCTA * ≥1 clinical risk factors (Smoking, HTN, HDL\<40, Premature FHx, M ≥45, F ≥55) for CAD
Exclusion criteria
* Acute coronary syndrome (unstable angina or MI) * Positive (not equivocal) stress test * Contraindications to statin
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Difference in percent change of total atheroma volume assessed by CCTA between statin-taking and statin-naïve group | 24 months | Patients indicated with statin therapy according to current guideline will receive atorvastatin. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change of total atheroma volume at 24 months compared with baseline total atheroma volume | 24 months | total atheroma volume assessed by CCTA |
Countries
South Korea
Contacts
Primary ContactHyuk-Jae Chang, MD, PhD
Backup ContactSang-Eun Lee, MD, PhD
Outcome results
None listed